18 and older, any sex, with T-cell Lymphoma or Angioimmunoblastic T-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Overall Response RatePrimary· Three years after end of treatment, up to 49 months
The primary objective is to evaluate overall response rate (ORR). Overall response rate will be estimated by the total number of patients who achieve a CR and PR divided by the total number of patients who received treatment. Response was assessed using CT scans according to the revised Cheson criteria.
* CR is defined as complete resolution of all clinically detectable disease and disease related symptoms that were present prior to therapy
* PR is defined as at least 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses Patients
Group
Value
95% CI
Brentuximab Vedotin
89.5
75.5 – 100
Complete ResponseSecondary· Three years after end of treatment, up to 49 months
Complete Response is defined as complete resolution of all clinically detectable disease and disease related symptoms that were present prior to therapy. A post-treatment residual mass of any size is permitted as long as it is PET negative. CR rate was calculated by dividing the total number of patients who have achieved a complete response by the total number of patients who received treatment.
Group
Value
95% CI
Brentuximab Vedotin
10.5
0 – 24.3
Progression Free SurvivalSecondary· Three years after end of treatment, up to 49 months
Progression-free survival (PFS) is defined as the time from treatment initiation into the study to disease progression or death due to any cause. The distribution of PFS will be estimated using the Kaplan-Meier method. Disease progression may be defined as the date of documentation of a new lesion or enlargement of a previous lesion, or the date of the scheduled clinic visit immediately after radiologic assessment has been completed. For a patient who is alive without progression at the end of study follow-up, observation of PFS is censored on the date of last contact.
Group
Value
95% CI
Brentuximab Vedotin
8.0
5.3 – 12.3
Overall SurvivalSecondary· Three years after end of treatment, up to 49 months
The overall survival (OS) is defined as the time from treatment initiation to the time of death due to any cause. For a patient who is alive at the end of study follow-up, observation of OS is censored on the date of last contact. The distribution of OS will be estimated using the Kaplan-Meier method.
Group
Value
95% CI
Brentuximab Vedotin
10.8
5.6 – 20.8
Duration of ResponseSecondary· Three years after end of treatment, up to 49 months
Duration of response (DOR) among responders is defined as the time from first documentation of objective tumor response (CR or PR) to the time of first progression or death due to any cause.
Group
Value
95% CI
Brentuximab Vedotin
5.4
2.8 – 17.6
Time to Treatment Failure (TTF)Secondary· Up to 13 months after start of treatment
Time to treatment failure (TTF) is defined as the time from treatment initiation to discontinuation of treatment for any reason, including disease progression, treatment toxicity, and death. Date of last follow-up was collected for patients who did not have disease progression, but it is unknown for which reasons treatment was stopped for these patients. In this case, time to treatment failure (TTF) is the same as time to progression.
Group
Value
95% CI
Brentuximab Vedotin
7.4
5.1 – 12.1
Time to Response (TTR)Secondary· Three years after end of treatment, up to 49 months
Time to treatment failure (TTR) is defined as time from treatment initiation to first documentation of objective tumor response (CR or PR).
Group
Value
95% CI
Brentuximab Vedotin
2.7
2.5 – 2.7
Adverse events — posted to ClinicalTrials.gov
Time frame: All AEs (regardless of relationship to study drug) captured from the time the subject signs the ICF through the end of the safety-reporting period, approximately 4 years..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This study will include patients with mature T-cell lymphoma (MTCL) that has been treated with at least one type of chemotherapy, but is not responding or coming back after the previous treatment.
This clinical trial uses a drug called Brentuximab Vedotin. The Food and Drug Administration (FDA) has approved Brentuximab Vedotin for sale in the United States for certain diseases. Brentuximab is still being studied in clinical trials like this one to learn more about what its side effects are and whether or not it is effective in the disease or condition being studied.
Brentuximab Vedotin is a type of drug called an antibody drug conjugate (ADC). ADCs usually have 2 parts; a part that targets cancer cells (the antibody) and a cell killing part (the chemotherapy). Antibodies are proteins that are part of your immune system. They can stick to and attack specific targets on cells. The antibody part of Brentuximab Vedotin sticks to a target called CD30. CD30 is an important molecule on some cancer cells (including non Hodgkin lymphoma) and some normal cells of the immune system. The cell killing part of Brentuximab Vedotin is a chemotherapy called monomethyl auristatin E (MMAE). It can kill cells that the antibody part of Brentuximab Vedotin sticks to. Brentuximab Vedotin has also been shown to kill cancer cells with levels of CD30 that cannot be seen by traditional methods.
This study is being done to test if the study drug has an effect on Mature T cell Lymphoma with such low levels of a target called CD30 and how your disease respond to the study drug.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT05149768 — Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
· Phase 2
· recruiting
NCT05922904 — PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lym
· Phase 2
· active not recruiting
NCT05313243 — Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
· Phase 2
· recruiting
NCT05414500 — Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
· Phase 1
· recruiting
NCT05442554 — A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma
· Phase 4
· completed
Other recruiting trials for T-cell Lymphoma
Currently open trials in the same condition.
NCT07388563 — Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
· Phase 1
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Deepa Jagadeesh
Last refreshed: 21 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02588651.